TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02726191

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Story Recall Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sample-Match (Within Modality) Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pair-Match (Across-Modality) Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Triad-FiguresExercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monster Garden Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Match Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Matrix Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Familiar Faces Exercises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lost in Migration Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Playing Koi Exercise
Study: NCT02302183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeO2 v2.0 automatic adjustment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FreeO2 v2.0 data collecting
Study: NCT02068118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telecardiology program
Description: The telecardiology program is a combination of a scale, a device asking the patients questions about the symptoms associated with their heart failure, and regular phone calls made by nurses.~Automatic algorithms have been built-up in order to detect early the need for a hospitalization due to heart failure.
Study: NCT02884375

Intervention type: OTHER
Intervention: Extensive GA
Description: GA includes an evaluation of nine domains according to international recommendations :~* functional status (six-item Activities of Daily Living (ADL) score, Instrumental Activities of Daily Living (IADL))~* mobility (timed get-up-and-go test, one-leg standing balance test, history of fall)~* nutritional status (French National Authority of Health guidelines, weight loss body mass index (BMI), Mini Nutritional Assessment, albumin )~* cognitive status (Mini-Mental State Examination (MMSE), history of dementia, confusion)~* mood (Mini-Geriatric Depression Scale (Mini-GDS), symptoms of anxiety, depression (DSM V))~* comorbidities (CIRS G)~* polypharmacy (number of medications)~* social environment (primary caregiver, support at home, friends , family, living alone)~* urinary and/or fecal incontinence
Study: NCT04094233

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot extract
Description: Ingestion of 600mg beetroot extract two hours before strength exercise (75% 1RM).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot extract
Description: Ingestion of 600mg beetroot extract two hours before strength exercise (75% 1RM).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Ingestion of 600mg starch two hours before strength exercise (75% 1RM).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Ingestion of 600mg starch two hours before strength exercise (75% 1RM).
Study: NCT00624780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 150-300 mg given twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Lorazepam 3-4 mg given twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 450-600 mg given twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03816280

Intervention type: PROCEDURE
Intervention: Elective cardiopulmonary bypass (CPB)
Description: All groups undergo elective cardiopulmonary bypass (CPB)

Intervention type: PROCEDURE
Intervention: Elective cardiopulmonary bypass (CPB)
Description: All groups undergo elective cardiopulmonary bypass (CPB)

Intervention type: PROCEDURE
Intervention: Elective cardiopulmonary bypass (CPB)
Description: All groups undergo elective cardiopulmonary bypass (CPB)

Intervention type: PROCEDURE
Intervention: Elective cardiopulmonary bypass (CPB)
Description: All groups undergo elective cardiopulmonary bypass (CPB)
Study: NCT02404038

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nuvaring
Description: Nuvaring is the trade name for a combined hormonal contraceptive intravaginal ring, inserted once every 28 days, and removed after 21 days. The flexible plastic ring works in a similar way to the oral contraceptive pill to prevent pregnancy. It contains etonogestrel/ethinyl estradion and delivers 0.120mg/0.015mg per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triphasil
Description: Triphasil is a daily oral contraceptive: 21 active tablets followed by 7 inert tablets, starting initially on first day of menstrual cycle~Composition:~The six brown tablets of TRIPHASIL contain 30 µg ethinyl oestradiol and 50 µg levonorgestrel.~The five white tablets contain 40 µg ethinyl oestradiol and 75 µg levonorgestrel.~The ten yellow tablets contain 30 µg ethinyl oestradiol and 125 µg levonorgestrel.~The seven red tablets are inert
Study: NCT03816280

Intervention type: PROCEDURE
Intervention: Alpha-stat acid-base management
Description: Acid-base status during CPB will be maintained using the alpha-stat regime

Intervention type: PROCEDURE
Intervention: Alpha-stat acid-base management
Description: Acid-base status during CPB will be maintained using the alpha-stat regime
Study: NCT00979862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilengitide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00838968

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon-alpha
Description: interferon-alpha is intramuscularly or subcutaneously injected at 3,000,000-5,000,000 U three times a week for 18 months
Study: NCT04016727

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: Platelet rich plasma was prepared using patients own blood. 60 units of PRP was injected on one side of the arch using insulin syringe. Each patient served as his/her own control (the side with PRP injected) and experimental group (the side without PRP injected). Whether the right or left side served as control or experimental was determined by lottery method. Patients were recalled after 4 weeks and the measurements were repeated again between lateral incisors and canines at mid, cervical and incisal of the teeth and their mean was recorded.
Study: NCT01086267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-908662
Description: Capsules, Oral, escalating doses starting at 25 mg, every 12 hours (Q 12 h), Continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-908662
Description: Capsules, Oral, (TBD) mg, Q 12 h, Continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-908662
Description: Capsules, Oral, (TBD) mg, Q 12 h, Continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Vial, IV, 400 mg/m² loading dose followed by 250 mg/m² maintenance dose, Weekly, Continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Vial, IV, 400 mg/m² loading dose followed by 250 mg/m² maintenance dose, Weekly, Continuously
Study: NCT04566523

Intervention type: OTHER
Intervention: telerehabilitation
Description: Patients undergo an online exercise training program via a certified host of health data website.
Study: NCT04450862

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural therapy self help intervention for anxiety
Description: The intervention will involve five key components:~Psychoeducation - Increase awareness of how PH may affect emotional health, normalisation of difficulties, and discussion of how symptoms associated with anxiety may add to the burden of the disease.~Cognitions - Identify and challenge negative automatic thoughts associated with anxiety.~Coping skills - Educate and practice a range of behavioural coping methods to help participants better manage their physical symptoms associated with anxiety in PH.~Exposure - Replace avoidance of anxiety provoking situations and activities using graded exposure.~Relapse prevention - Focus on relapse prevention with implementation intentions and promotion of problem solving.
Study: NCT03816280

Intervention type: PROCEDURE
Intervention: pH-stat acid-base management
Description: Acid-base status during CPB will be maintained using the pH-stat regime
Study: NCT02022098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: A total of three cycles of cisplatin will be administered in a 1-hour IV infusion on days 2, 23 and 44. Cisplatin will be administered 0.5 hours after Debio 1143.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: A total of three cycles of cisplatin will be administered in a 1-hour IV infusion on days 2, 23 and 44. Cisplatin will be administered 0.5 hours after Debio 1143.
Study: NCT04187586

Intervention type: OTHER
Intervention: Extracorporeal shock wave therapy
Description: ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 6 sessions.
Study: NCT00425191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel and Gemcitabine
Description: Docetaxel: 40 mg/m², administered IV over 60 minutes (infusion drop by drop during the first five minutes) on day 1 and 8 immediately followed by Gemcitabine: 1200 mg/m2, administered IV over 30 minutes on day 1 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel and Gemcitabine
Description: Docetaxel: 50 mg/m², administered IV over 60 minutes (infusion drop by drop during the first five minutes) on day 1 and 15 immediately followed by Gemcitabine: 1600 mg/m2, administered IV over 30 minutes on day 1 and 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine cisplatin followed by docetaxel
Description: Gemcitabine: 1200 mg/m2, administered IV over 30 minutes on day 1 and 8 followed by Cisplatin 75 mg/m2, administered IV over 30-60 minutes on day 2
Study: NCT01969227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subanesthetic ketamine
Description: Ketamine drip at a subanesthetic infusion rate (low dose ketamine 5 - 10 mcg/kg/min)
Study: NCT00554424

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lignocaine
Description: 20 mls of 1% lignocaine solution for injection, 10mls into each side of upper vagina, under ultrasound guidance immediately prior to transvaginal oocyte retrieval under ultrasound guidance from each ovary

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 20mls of normal saline solution, 10mls injected each side into upper vagina under ultrasound guidance, immediately prior to ultrasound guided transvaginal oocyte retrieval from each ovary
Study: NCT01060150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS Methylphenidate HCl
Description: Osmotic Release Oral System (OROS) Methylphenidate HCl tablet will be given orally once daily at a starting dose of 18 milligram (mg) for those less than 30 kilogram (kg) of body weight and 27 mg for those more than or equal to 30 kg; the dose can be increased by 9 mg or 18 mg per week up to Week 6 depending on a participant's treatment effect and tolerability; then a maximum maintenance dose of 72 mg will be given orally once daily up to Week 12.
Study: NCT03884049

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embolization
Description: transcatheter arterial embolization of neovessels around the knee

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham embolization
Description: Sham transcatheter arterial embolization of neovessels in the knee
Study: NCT03138798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laboraide TM dental support device
Description: Patients will give consent in the first stage of labor. Subsequently a randomization will be performed using sealed envelopes opened at the time of pushing in the second stage of labor. Women assigned to Group A will received a sealed Laboraide TM package. Duration of the second stage and time spent pushing will be recorded. Obstetric management will not be altered by group assignment. Following delivery, patients assigned to Group A will complete a patient satisfaction survey.
Study: NCT00728572

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Logan Basic Technique and Surface EMG
Description: Participant will receive a brief Basic Technique and Surface EMG examination and Basic Technique treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surface EMG
Description: Surface EMG only, no intervention

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Surface EMG
Description: Surface EMG only, no intervention

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Logan Basic Technique Sham
Description: Participants will receive a sham Basic Technique treatment, not indicated by examination.
Study: NCT03111771

Intervention type: PROCEDURE
Intervention: carcinological surgery
Description: carcinological surgery for Group K +

Intervention type: PROCEDURE
Intervention: cervical surgery
Description: cervical surgery for Group K-

Intervention type: PROCEDURE
Intervention: cervical surgery
Description: cervical surgery for Group K-
Study: NCT03535389

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Knee 4DCT
Description: Dynamic knee 4DCT

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Knee 4DCT
Description: Dynamic knee 4DCT
Study: NCT01596738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 1. Tranexamic acid 50mg/ml, 15 mg/kg intravenous after anesthetic induction~2. Tranexamic acid 50mg/ml, 15 mg/kg intravenous after neutralization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 1. Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after anesthetic induction~2. Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after neutralization
Study: NCT01221389

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Plasma
Description: Patients will receive either 2 units of AB+ plasma or 2 units of hydroxyethylated starch control solution once they are sent to the OR for emergency surgery to address etiology for hemorrhagic shock.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Plasma
Description: Patients will receive either 2 units of AB+ plasma or 2 units of hydroxyethylated starch control solution once they are sent to the OR for emergency surgery to address etiology for hemorrhagic shock.
Study: NCT03986411

Intervention type: OTHER
Group type: OTHER
Intervention: Phase 1: Qualitative interviews: Health care professionals
Description: Semi-structured interviews of health care professionals to explore current management of urinary incontinence in the community

Intervention type: OTHER
Group type: OTHER
Intervention: Phase 2: Physiotherapy for urinary incontinence
Description: Tailored physiotherapy assessment and management for athletic women who self-report urinary incontinence

Intervention type: OTHER
Group type: OTHER
Intervention: Phase 3: Qualitative Interviews: Participants
Description: Semi-structured interviews of a purposeful selection of the participants from Phase 2 to explore reaction to the recruitment process and the intervention
Study: NCT01066637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F](+/-)NOS
Description: Injection of radiotracer \[18F\](+/-)NOS for PET imaging and kinetic data analysis
Study: NCT02022098

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Standard fraction radiotherapy to the primary tumour will be delivered daily for 5 days per week over 7 weeks.
Study: NCT04032717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q-Griffithsin (Q-GRFT) enema
Description: Investigational enema composed of 4.2mL Q-Griffithsin (Q-GRFT) 9.6mg/mL combined with approximately 120.8mL of 0.9% sodium chloride solution to yield an active enema study product that will contain and deliver a dose of approximately 40mg of Q-GRFT
Study: NCT00725244

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar eletrocoagulation
Description: Bipolar Eletrocoagulation was performed with a high-frequency electrosurgical generator (ERBE® ICC 200 Eletromedizin, Tubingen, Germany), using Gold probe (Wilson- Cook®) with 7 Fr diameter and 300 cm length. The power setting was 50 W. Coagulation of each telangiectasia was achieved with the probes by applying light pressure directly on the telangiectasia.
Study: NCT04032717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q-Griffithsin (Q-GRFT) enema
Description: Investigational enema composed of 4.2mL Q-Griffithsin (Q-GRFT) 9.6mg/mL combined with approximately 120.8mL of 0.9% sodium chloride solution to yield an active enema study product that will contain and deliver a dose of approximately 40mg of Q-GRFT

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo enema
Description: Approximately 125mL of 0.9% sodium chloride solution
Study: NCT05107596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 64Cu-DOTA-ECL1i
Description: Inject PET Radioisotope for imaging

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 64Cu-DOTA-ECL1i
Description: Inject PET Radioisotope for imaging

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 64Cu-DOTA-ECL1i
Description: Inject PET Radioisotope for imaging

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 64Cu-DOTA-ECL1i
Description: Inject PET Radioisotope for imaging

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 64Cu-DOTA-ECL1i
Description: Inject PET Radioisotope for imaging
Study: NCT02022098

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: Standard fraction radiotherapy to the primary tumour will be delivered daily for 5 days per week over 7 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1143
Description: Debio 1143 solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo solution
Study: NCT04334902

Intervention type: DEVICE
Intervention: mPDia
Description: Clinical decision support system for diagnosing neurodegenerative parkinsonism

Intervention type: DEVICE
Intervention: mPDia
Description: Clinical decision support system for diagnosing neurodegenerative parkinsonism
Study: NCT04182165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gili BioSensor System/ Gili Pro X BioSensor System
Description: Usability study

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gili BioSensor System/ Gili Pro X BioSensor System
Description: Usability study
Study: NCT00476502

Intervention type: GENETIC
Intervention: identify genetic polymorphism in Thai HIV infected
Description: Gene sequencing of Cyp450 metabolic pathway
Study: NCT02485340

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-ISMN (isosorbide-5-mononitrate)
Description: 5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-ISMN (isosorbide-5-mononitrate)
Description: 5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan
Description: 5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Study: NCT00725244

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Argon Plasma Coagulation
Description: Argon plasma coagulation was delivered using a spray-painting technique, with short applications at 40 W power with a gas flow of 1.0l per minute. APC equipment was an argon delivery unit (ERBE® ICC 300) coupled a high frequency surgery unit (ERBE® ICC 200). Only the end-firing probe with 2.3 mm and 220 cm length was used. The probe was purged with argon, tested and passed though the endoscope until it extends approximately 1 cm from the tip. The probe was hold just above the mucosal surface and the contact was avoided. During the procedure periodic suction was made to prevent over-distention with gas and consequently patient discomfort.
Study: NCT01273506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tapentadol (CG5503) ER 25-mg TRF
Description: 50 mg TRF single oral dose
Study: NCT02402686

Intervention type: DRUG
Intervention: Tocilizumab
Description: Dosing and treatment duration of tocilizumab collected as part of this non-interventional study are at the discretion of the physician in accordance with local clinical practice and local labeling. Observation period is 24 weeks from first SC tocilizumab administration.
Study: NCT03476616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone (-based therapy) arm
Description: At randomization, pts meeting inclusion/exclusion criteria will be randomized (1:1) to either eplerenone (E) 25mg bd or valsartan (V) 160mg od for 8 wks. At 8, 16 and 24 wks, pts at both arms will be evaluated with ABPM primary, as well as home and office BP measurements. At wk 8, pts with controlled hypertension (mean ABPM \<130/80mmHg), will continue in monotherapy with eplerenone or valsartan and pts with uncontrolled hypertension (mean ABPM ≥130/80mmHg) will continue with the addition of amlodipine (C) 10mg od. At wk 16, pts achieving BP control will continue in either monotherapy (E), (V) or dual therapy (E+C), (V+C). However, in pts not achieving ABPM target, a third drug, will be added \[indapamide (D) 1.25 mg od\]. All groups at both arms will be evaluated at 24 wks by ABPM.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan (-based therapy) arm
Description: At randomization, pts meeting inclusion/exclusion criteria will be randomized (1:1) to either eplerenone (E) 25mg bd or valsartan (V) 160mg od for 8 wks. At 8, 16 and 24 wks, pts at both arms will be evaluated with ABPM primary, as well as home and office BP measurements. At wk 8, pts with controlled hypertension (mean ABPM \<130/80mmHg), will continue in monotherapy with eplerenone or valsartan and pts with uncontrolled hypertension (mean ABPM ≥130/80mmHg) will continue with the addition of amlodipine (C) 10mg od. At wk 16, pts achieving BP control will continue in either monotherapy (E), (V) or dual therapy (E+C), (V+C). However, in pts not achieving ABPM target, a third drug, will be added \[indapamide (D) 1.25 mg od\]. All groups at both arms will be evaluated at 24 wks by ABPM.